Inozyme Pharma to Participate at the 22nd Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Inozyme Pharma (Nasdaq: INZY), a clinical-stage biopharmaceutical company focused on rare diseases, announced that Douglas A. Treco, Ph.D., CEO and Chairman, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on April 18, 2023, from 9:30 to 10:10 AM ET.

A live webcast of this event will be available on the Investor Relations section of Inozyme's website, along with a replay for a limited time.

Inozyme is developing INZ-701, an enzyme replacement therapy targeting pathologic mineralization and intimal proliferation associated with severe diseases. Currently, INZ-701 is in Phase 1/2 clinical trials for ENPP1 Deficiency and ABCC6 Deficiency.

BOSTON, April 11, 2023 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY), a clinical- stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of pathologic mineralization and intimal proliferation, today announced Douglas A. Treco, Ph.D., the company’s chief executive officer and chairman of the board, will participate in a fireside chat at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023 from 9:30-10:10am ET.

A live webcast of the fireside chat can be accessed from the Investor Relations section of Inozyme’s website under events, where a replay of the event will also be available for a limited time.

About Inozyme Pharma

Inozyme Pharma, Inc. (Nasdaq: INZY) is a clinical-stage rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue, and skeleton. We are developing INZ-701, an enzyme replacement therapy, to address pathologic mineralization and intimal proliferation which can drive morbidity and mortality in these severe diseases. INZ-701 is currently in Phase 1/2 clinical trials for the treatment of ENPP1 Deficiency and ABCC6 Deficiency.

For more information, please visit www.inozyme.com and follow us on LinkedIn, Twitter, and Facebook.

Contacts

Investors:
Inozyme Pharma
Stefan Riley, Director of IR and Corporate Communications
(857) 330-8871
stefan.riley@inozyme.com

Media:
SmithSolve
Matt Pera
(973) 886-9150
matt.pera@smithsolve.com

FAQ

What will Douglas A. Treco discuss at the Needham Conference for Inozyme Pharma (INZY)?

Douglas A. Treco will participate in a fireside chat discussing the latest developments and future directions of Inozyme Pharma at the Needham Conference on April 18, 2023.

When is Inozyme Pharma's presentation at the Needham Virtual Healthcare Conference?

Inozyme Pharma's presentation at the Needham Virtual Healthcare Conference is scheduled for April 18, 2023, from 9:30 to 10:10 AM ET.

How can I access the webcast of Inozyme Pharma's presentation?

The webcast can be accessed from the Investor Relations section of Inozyme Pharma's website, where a replay will also be available for a limited time.

What is INZ-701 and its significance to Inozyme Pharma (INZY)?

INZ-701 is an enzyme replacement therapy being developed by Inozyme Pharma to treat pathologic mineralization and intimal proliferation, currently in Phase 1/2 clinical trials.

What diseases are targeted by Inozyme Pharma's INZ-701 therapy?

INZ-701 targets ENPP1 Deficiency and ABCC6 Deficiency, which are severe diseases associated with morbidity and mortality.